ClinicalTrials.gg

Program

LW402

A development code. Also written as “Experimental LW402 Tablet” and “Drug: LW402”.

Its studies are mostly in Dermatitis, Atopic · Vitiligo · Arthritis, Rheumatoid, led by Shanghai Longwood Biopharmaceuticals.

Furthest: phase 3, since Jan 19, 20264 company-led studies, 2 open or runningNext primary completion: Feb 1, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Longwood Biopharmaceuticals42 open or runningphase 3since Jan 19, 2026Oct 11, 2024Feb 1, 2028phase 2 · NCT07556471

Also a collaborator on its studies: tigermed-consulting-co-ltd and clinical-service-china.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 11, 2024First study: phase 2 study in Arthritis, RheumatoidFirst studyNCT06800157 · 72 enrolled · China
  2. Sep 15, 2025Phase 2 study in Dermatitis, AtopicNCT07186387 · 144 enrolled · China
  3. Jan 19, 2026Phase 3 study in Moderate to Severe Atopic DermatitisPhase 3 reachedNCT07370909 · 480 planned · China
  4. Apr 16, 2026Phase 2 study in Non-Segmental Vitiligo (NSV)NCT07556471 · 180 planned

Ahead

  1. Feb 1, 2028Primary completion: phase 2 study in Non-Segmental Vitiligo (NSV)NCT07556471
  2. Mar 31, 2028Primary completion: phase 3 study in Moderate to Severe Atopic DermatitisNCT07370909

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07556471Non-Segmental Vitiligo (NSV)2Not yet recruitingFeb 1, 2028180
NCT07370909Moderate to Severe Atopic Dermatitis · China3RecruitingMar 31, 2028480
NCT07186387Dermatitis, Atopic · China2CompletedSep 25, 2024144
NCT06800157Arthritis, Rheumatoid · China2CompletedMay 26, 202472

How it is read

Names in the registry

  • “LW402”, 2 entries
  • “Experimental LW402 Tablet”, 1 entry
  • “Drug: LW402”, 1 entry

Codes read as this program: LW402.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.